About OpGen
OpGen is a publicly listed company based in Rockville (United States) founded in 2002. Developer of diagnostics and bioinformatics platforms for providers. OpGen has raised $77.51 million across 19 funding rounds from investors including European Union, 180 Degree Capital and Merck Global Health Innovation Fund. The company has 4 employees. OpGen has completed 1 acquisition, including Curetis. Its chief executive, as recorded, is Oliver Schacht. OpGen offers products and services including Molecular Microbiology Services and CapForce Fintech Arm. Its focus areas include Life Sciences, Genomics, Applied Genomics and Clinical Genomics. Its competitors include Karius, Day Zero Diagnostics and Clear Labs; 3 of its 3 listed competitors have raised funding.
Company details
Founded in 2002 and headquartered in Rockville, United States, OpGen operates in the diagnostics and bioinformatics sector. Platforms and tests, including the Acuitas MDRO Gene Test, Acuitas Lighthouse MDRO Management System, and Acuitas Resistome Test, are provided to healthcare providers. These tools support the detection of multi-drug resistant organisms in hospital patients, aiding infection management efforts.
- Annual Revenue$5.2 M (USD)52.01as on Dec 31, 2024
- Net Profit$11.99 M (USD)as on Dec 31, 2024
- EBITDA$574.63 K (USD)as on Dec 31, 2024
- Total Equity Funding$77.51M (USD)
in 19 rounds
- Latest Funding Round$25M (USD), Post-IPO
Feb 2021
- InvestorsEuropean Union
& 12 more
- Employee Count4
- Investments & Acquisitions
Products & Services of OpGen
OpGen offers a comprehensive portfolio of products and services, including Molecular Microbiology Services and CapForce Fintech Arm.
Offers solutions to combat antimicrobial resistance using advanced techniques.
Provides financial technology solutions as a new business expansion.
Funding Insights of OpGen
OpGen has successfully raised a total of $77.51M across 19 strategic funding rounds. The most recent funding activity was a Post-IPO round of $25 million completed in February 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $77.51M
- Total Rounds 19
- Last Round Post-IPO — $25M
- First Round $5M
(Jan 2005)
- Investors Count 13
Latest 10 of 19 funding rounds of OpGen with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Feb 2021 | $25M | Post-IPO | – | – | – |
| Dec 2020 | $9.97M | Post-IPO | – | – | – |
| Jul 2018 | $285,512 | Post-IPO | – | – | – |
| Sep 2017 | $110,000 | Post-IPO | – | – | – |
| Jun 2017 | $500,000 | Post-IPO | – | – | – |
| May 2016 | $10.4M | Post-IPO | – | – | |
| Jul 2015 | $6M | Post-IPO | – | – | |
| Jun 2015 | Grant | – | – | ||
| Feb 2015 | $1.24M | Series C | – | – | – |
| Jul 2014 | $1.08M | Series C | – | – | – |
13 investors in total: 13 institutional.
Investors in OpGen
OpGen has secured backing from 13 investors, including venture fund and institutional investors. Prominent investors backing the company include European Union, 180 Degree Capital and Merck Global Health Innovation Fund.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Corporate-backed venture capital is focused on the life science sector. | merckghifund.com | Kenilworth, United States | ||
Venture capital investment and entrepreneur support services. | hcp.com | |||
Venture capital firm managing investments in biotechnology and pharmaceuticals since 1999. | versantventures.com | |||
Growth-stage US life sciences investments are targeted by jVen Capital. | jvencapital.com | Wyoming, United States | ||
Early stage healthcare services investments are facilitated by CHL. | chlmedical.com | Westport, United States | ||
VC firm funding companies in the US | 1981 | 180degreecapital.com | Montclair, United States | |
Sector-agnostic investments in late-stage startups are made by Cross Creek. | crosscreek.vc | Salt Lake City, United States | ||
| masonwells.com | ||||
Venture capital firm | iqt.org | Washington, Dc, United States | ||
US private equity investments are managed by Stonehenge Capital. | stonehengecapital.com | Baton Rouge, United States |
Investor details for OpGen
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of OpGen
14 people are tracked at OpGen (3 in leadership, 8 in board & advisors, 3 in team); the tracked headcount is 4.
| Name | Role | Group |
|---|---|---|
Oliver Schacht | CEO & President | Leadership |
Johannes Bacher | Chief Operating Officer | Leadership |
Arne Materna | Managing Director & CEO, Ares Genetics | Leadership |
Prabhavathi Fernandes | Director | Board & advisors |
Debra A. Goff | Advisor | Board & advisors |
Patricia Simner | Advisor | Board & advisors |
James W. Snyder | Advisor | Board & advisors |
Stefan Riedel | Advisor | Board & advisors |
Don Elsey | Director | Board & advisors |
Mario Crovetto | Director | Board & advisors |
Yvonne Schlaeppi | Director | Board & advisors |
Nikhil Toraskar | Senior Bioinformatics Scientist | Team |
David Caplon | Corporate Controller | Team |
Huan Wang | Clinical Application Specialist | Team |
Complete people profiles for OpGen
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of OpGen
OpGen is a publicly listed company on the OTC with ticker symbol OPGN in USA, operating in the Commercial services sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date14 Apr 2021
- Listed onLSE: 0A8L
- Listed entityOpGen, Inc.
- Exchange sectorCommercial services
- ISINUS68373L5057
- Share price$24.75 (+3.13% on the day) · 2026-03-04
- Market capitalisation$301.4M
- Price to earnings61.9
- EPS (diluted, trailing year)$0.40
- Volume (last session)110
- Analyst consensusNo rating
Financials of OpGen
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2024 | $5.2M | $12.0M | $574,630 |
| 2023 | $3.4M | -$32.7M | -$14.4M |
| 2022 | $2.6M | -$37.3M | -$20.6M |
| 2021 | $4.3M | -$34.8M | -$20.4M |
| 2020 | $4.2M | -$26.2M | -$19.2M |
Detailed financial statements for OpGen
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Investments & Acquisitions by OpGen
OpGen has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Curetis.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Molecular diagnostics platform is provided for infectious disease detection. | curetis.com | Holzgerlingen, Germany | 2007 | Sep 2019 | •••• |
Complete acquisition details for OpGen
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of OpGen
5 dated milestones of OpGen across 19 years, from founding to its latest funding, stage changes and deals.
- Founded OpGen is founded.
- Funding First funding round of $5.0M.
- Acquisition Acquires Curetis.
- Funding Latest funding round, Post-IPO, of $25.0M.
- IPO Lists on the stock exchange (IPO).
Competitors of OpGen
OpGen has 3 listed competitors in our database, 3 of them funded. They include Karius, Day Zero Diagnostics and Clear Labs.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| kariusdx.com | 2014 | Redwood, United States | $315M | 139 | Developer of a non-invasive pathogen blood test for the detection of infectious diseases | |
| dayzerodiagnostics.com | 2016 | Boston, United States | $48.6M | 48 | Genome sequencing diagnostics for infectious diseases are developed. | |
| clearlabs.com | 2014 | Menlo Park, United States | $171.09M | 55 | Food safety technologies are provided for pathogen identification. |
Detailed competitors of OpGen
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of OpGen
The website of OpGen (opgen.com) receives about 2.7K visits a month.
- Monthly visits2.7K
▲ 15% vs previous month
Websites whose visitors overlap most with OpGen. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
plosbiology.org | plosbiology.org | 100% | – | ||
genedb.org | genedb.org | 94% | – | ||
aspergillusgenome.org | aspergillusgenome.org | 93% | – | ||
schatzlab.cshl.edu | schatzlab.cshl.edu | 93% | – | ||
bioviz.org | bioviz.org | 93% | #2,498,706 | – | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 12 similar websites and full traffic analytics for OpGen
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 12 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as OpGen (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Opgen
Complete news archive for OpGen
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about OpGen
OpGen was founded in 2002 and raised its 1st funding round 3 years after it was founded.
OpGen is headquartered in Rockville, United States. It is registered at Rockville, Maryland, United States.
Oliver Schacht is the CEO of OpGen, as recorded in our data.
OpGen is a funded company, having raised a total of $77.51M across 19 funding rounds to date. The company's 1st funding round was a Series C of $1.08M, raised on Jan 2005.
OpGen has 4 employees.
Annual revenue of OpGen is $5.2M as on Dec 31, 2024.
Founded in 2002 and headquartered in Rockville, United States, OpGen operates in the diagnostics and bioinformatics sector. Platforms and tests, including the Acuitas MDRO Gene Test, Acuitas Lighthouse MDRO Management System, and Acuitas Resistome Test, are provided to healthcare providers. These tools support the detection of multi-drug resistant organisms in hospital patients, aiding infection management efforts.
OpGen's top competitors include Clear Labs, Day Zero Diagnostics and Karius.
OpGen offers Molecular Microbiology Services and CapForce Fintech Arm.
Yes, OpGen is publicly traded on OTC under the ticker symbol OPGN.
OpGen has made 1 acquisition, including Curetis.
OpGen has 13 investors. Key investors include European Union, 180 Degree Capital, Merck Global Health Innovation Fund, Highland Capital Partners, and Versant Ventures.